Hervé Bonnefoi
A5056811246- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Gene expression and cancer classification
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Global Cancer Incidence and Screening
- Genetic factors in colorectal cancer
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Ovarian cancer diagnosis and treatment
- Cancer Risks and Factors
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
Institut Bergonié
2016-2025
Université de Bordeaux
2016-2025
Inserm
2016-2025
Cancer Clinic
2025
NSABP Foundation
2012-2025
National Cancer Institute
2025
National Center for Tumor Diseases
2025
Helios Hospital Berlin-Buch
2012-2025
European Organisation for Research and Treatment of Cancer
2003-2024
Sonnenhalde (Switzerland)
2023
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
Suppression of ovarian estrogen production reduces the recurrence hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.We randomly assigned 3066 stratified according prior receipt or nonreceipt chemotherapy, receive 5 years tamoxifen, plus suppression, exemestane suppression. The primary analysis tested hypothesis that suppression would improve disease-free survival, as compared with alone. In analysis, 46.7% patients had...
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic (mBC) is associated with poor outcomes, yet limited information available on profile this disease. This study aims to decipher mutational profiles mBC using next-generation sequencing.Whole-exome sequencing was performed 216 tumor-blood pairs from patients who underwent a biopsy context SAFIR01, SAFIR02, SHIVA, or Molecular Screening for Cancer Treatment Optimization (MOSCATO)...
APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 1.00], P = .045) for patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), specifically those node-positive or hormone (HR)-negative disease. We now report the preplanned second interim overall (OS) descriptive updated IDFS analysis 74...
About one third of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) will relapse. Thus, additional therapy is needed. Palbociclib a cyclin-dependent kinase 4 and 6 inhibitor demonstrating efficacy in the metastatic setting. PENELOPE-B (NCT01864746) double-blind, placebo-controlled, phase III study women primary without pathological complete response...
The 18th St Gallen International Breast Cancer Conference held in March 2023, Vienna, Austria, assessed significant new findings for local and systemic therapies early breast cancer with a focus on the evaluation of multimodal treatment options. emergence more effective, innovative agents both preoperative (primary or neoadjuvant) post-operative (adjuvant) settings has underscored pivotal role multidisciplinary approach decision making, particularly when selecting therapy an individual...
JCO